Authors: | Park, W.; O'Connor, C.; Chou, J.; Schwartz, C.; Larsen, M.; Varghese, A.; Yu, K.; Balogun, F.; Yang, J.; Katz, S.; Kelsen, D.; Umeda, S.; Bandlamudi, C.; Riaz, N.; Berger, M.; Balachandran, V.; Peer, D.; Capanu, M.; Iacobuzio-Donahue, C.; O'Reilly, E. M. |
Abstract Title: | Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum |
Meeting Title: | ESMO Congress 2024 |
Journal Title: | Annals of Oncology |
Volume: | 35 |
Issue: | Suppl. 2 |
Meeting Dates: | 2024 Sep 13-17 |
Meeting Location: | Barcelona, Spain |
ISSN: | 0923-7534 |
Publisher: | Oxford University Press |
Date Published: | 2024-09-01 |
Start Page: | S922 |
Language: | English |
ACCESSION: | WOS:001326612902126 |
DOI: | 10.1016/j.annonc.2024.08.1567 |
PROVIDER: | wos |
Notes: | Meeting Abstract: 1504MO -- Source: Wos |